Citation: | QU Yakun, LI Xin, CHEN Ting, XU Ying, LIN Na. Effects of fulvestrant on the estrogen receptor expression in uterus and vagina of immature mice[J]. Journal of China Pharmaceutical University, 2016, 47(2): 210-214. DOI: 10.11665/j.issn.1000-5048.20160214 |
[1] |
Zhou ES,Wang S,Dong CE.The progress on the development of selective estrogen receptor down regulator(SERDs)and their molecular biological mechanism[EB/OL].[2013-02-05] .http://www.paper.edu.cn/releasepaper/content/201302-99.
|
[2] |
Zhang Y,Wang JH,Sun H,et al.Effect and safety of fulvestrant in the treatment of patients with receptor-positive metastatic breast cancer[J].China Prac Med(中国实用医药),2014,9(21):1-3.
|
[3] |
Liu KH,Cao RX.The research progression is the resistance to endocrine therapy in breast cancer in vitro[J].J Pract Oncol(实用肿瘤杂志),2015,25(9):494-498.
|
[4] |
Zhang Y.Vascular protective effects and mechanism research of PQS on postmenopausal women with coronary heart disease(西洋参茎叶总皂苷对绝经后女性冠心病患者的血管保护效应及机制研究)[D].Beijing:China Academy of Chinese Medical Sciences,2013.
|
[5] |
Ma XP,Xu Y,Ding J,et al.Effects of estradiol valerate on the estrogen receptor espression in uterus,vagina and mammary gland of ovariectomized rats[J].J China Pharm Univ(中国药科大学学报),2014,45(3):341-345.
|
[6] |
Lu HY,Cai JF,Wang XJ.The research progress of clinical application of fulvestrant[J].J Prac Oncol(实用肿瘤杂志),2012,27(5):562-564.
|
[7] |
Tan WH, Liu W, Guan YM. The research progress is between estrogen receptor subtypes and gynecological tumors[J].Chin J Birth Health Hered(中国优生与遗传杂志),2005,13(6):116-126.
|
[8] |
Zheng ZH,Liu P.Fulvestrant[J].Chin J New Drugs(中国新药杂志),2004,13(1):78-79.
|
[9] |
Jiang H,Wang T,Jiang ZF.Some clinical issues of fulvestrant for the treatment of breast cancer[J].Clin Medica J(临床药物治疗杂志),2012,10(2):9-13.
|
[10] |
Chen M,Zhao PW,Sun LP,et al.The effect of estrogen receptors in gynecological malignancies[J].China Med(中国医药),2015,10(6):926-928.
|
[11] |
Jiang H,Wang T,Zhang SH,et al.Fulvestrant for the treatment of advanced breast cancer after prior aromatase inhibitor therapy[J].China Oncol(中国癌症杂志),2013,23(3):224-228.
|
[12] |
Wu MH,Wang M,Wang W,et al.Combination of fulvestrant and trastuzumab for the treatment of Luminal B(HER-2 positive)advanced breast cancers after prior aromatase inhibitors[J].Chin Clin Oncol(临床肿瘤学杂志),2014,6(19):512-515.
|
[13] |
Agrawal A,Robertson JF,Cheung KL,et al.Biological effects of fulvestrant on estrogen receptor positive human breast cancer:short,medium and long-term effects based on sequential biopsies[J].Int J Cancer,2016,138(1):146-159.
|
[14] |
Quenel-Tueux N, Debled M, Rudewicz J, et al. Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer[J].Brit J Cancer,2015,113(4):585-594.
|
[1] | ZHANG Huili, LI Ke, ZHAO Hui, HU Guoqiang, HUANG Wenlong. Synthesis and antitumor activity of fluoroquinolone C-3 s-triazole Schiff-base carboxylic acid derivatives from pefloxacin(X)[J]. Journal of China Pharmaceutical University, 2017, 48(2): 167-171. DOI: 10.11665/j.issn.1000-5048.20170206 |
[2] | GAN Xia, NIAN Siyun, WANG Guoping. Advances in the development of farnesoid X receptor antagonists[J]. Journal of China Pharmaceutical University, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503 |
[3] | WANG Jianming, CHEN Yanmei, ZHANG Hailu, ZHANG Yanfeng, CHEN Minhua. Crystal form identification of dasatinib in tablets[J]. Journal of China Pharmaceutical University, 2015, 46(5): 575-578. DOI: 10.11665/j.issn.1000-5048.20150510 |
[4] | LIU Congbiao, GUO Zhen, LI Biao, WANG Jincan, YIN Xianzhen, ZHUWeifeng, WANG Liuyi, ZHANG Jiwen. Investigation of microstructures of freeze-dried orally disintegrating tablets by synchrotron radiation X-ray computed microtomography[J]. Journal of China Pharmaceutical University, 2014, 45(1): 48-53. DOI: 10.11665/j.issn.1000-5048.20140108 |
[5] | WANG Qi-zhi, LIANG Jing-yu, FENG Xu. X-ray crystallographic analysis and revision of NMR spectral assignments for rhetsinine[J]. Journal of China Pharmaceutical University, 2009, 40(6): 503-505. |
[6] | X-Ray Diffraction Fourier Fingerprint Pattern Analysis for Qingkailing Patent Medicine[J]. Journal of China Pharmaceutical University, 2004, (2): 41-43. |
[7] | Identification of Nateglinide and Its Crystal Forms in Nateglinide Tablets Using IR Spectra Subtraction Techniques[J]. Journal of China Pharmaceutical University, 2002, (2): 46-48. |
[8] | Determination of Polydimethylsiloxane in Meteospasmyl Capsules by IR[J]. Journal of China Pharmaceutical University, 1997, (3): 34-36. |
[9] | Microscopic Identification of the Powder of Chinese Drug Mai-Dong (Radix Ophiopognis)[J]. Journal of China Pharmaceutical University, 1992, (1): 5-10. |
[10] | MICROSCOPICAL IDENTIFICATION OF POWDERED ANIMAL DRUGS[J]. Journal of China Pharmaceutical University, 1985, (4): 27-34. |